OptimizeRx Corp (NASDAQ:OPRX) shares are tumbling on Friday as the company faces increased market volatility and uncertainty surrounding Most Favored Nation (MFN) pricing.
Earnings Exceed Expectations
The company recently reported fourth-quarter earnings of 51 cents, better than the consensus estimate of 23 cents.
Revenues jumped to $32.2 million, compared to the consensus of $31.1 million, with adjusted EBITDA of $12.0 million.
However, Lower 2026 Forecasts
OptimizeRx updated its fiscal year 2026 guidance, expecting revenue between $109 million and $114 million, down from prior guidance of $118 million-$124 million, while adjusted EBITDA is projected to fall between $21 million and $25 million.
This guidance comes amid a backdrop of cautious spending from customers, which may create near-term headwinds for the company.
OptimizeRx CEO Expects Uncertainty
“We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation (MFN) pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration. While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business,” Stephen Silvestro, OptimizeRx CEO, commented.
“In addition, we believe advancements in AI will enable customers to reallocate marketing dollars from content creation toward reach and execution—areas where we provide differentiated value with significant ROIs, further strengthening our position over time,”
Technical Analysis
Currently, the stock is trading 19.7% below its 20-day simple moving average (SMA) and 50.1% below its 100-day SMA, indicating a bearish trend.
Over the past 12 months, shares have increased by 42.80%, but they are currently positioned closer to their 52-week lows than highs, suggesting a potential struggle for upward momentum.
The RSI is at 34.00, which is considered neutral territory, while the MACD shows a value of -1.0014, with the signal line at -1.0696, indicating bullish momentum as the MACD is above the signal line.
This combination suggests that while the stock is currently under pressure, there may be potential for a rebound if market conditions improve.
- Key Resistance: $8.50
- Key Support: $6.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $23.08. Recent analyst moves include:
- Stifel: Buy (Lowers Target to $17.00) (Mar. 6)
- Stephens & Co.: Equal-Weight (Lowers Target to $17.00) (Nov. 17, 2025)
- Citizens: Market Outperform (Raises Target to $24.00) (Nov. 7, 2025)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for OptimizeRx, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 0.51 — Stock is performing poorly relative to peers.
- Quality Rank: 29.84 — Balance sheet remains healthy.
- Momentum Rank: 29.51 — Stock is underperforming the broader market.
The Verdict: OptimizeRx’s Benzinga Edge signal reveals a classic ‘High-Flyer’ setup. While the Quality rank indicates a healthy balance sheet, the low Value and Momentum scores suggest that the stock is currently underperforming and may face challenges in the near term.
OPRX Price Action: OptimizeRx shares were down 17.53% at $6.21 at the time of publication on Friday, according to Benzinga Pro data.
Image via Imagn Images
